PL2236151T3 - Ligandy receptora melanokortyny - Google Patents
Ligandy receptora melanokortynyInfo
- Publication number
- PL2236151T3 PL2236151T3 PL10170694T PL10170694T PL2236151T3 PL 2236151 T3 PL2236151 T3 PL 2236151T3 PL 10170694 T PL10170694 T PL 10170694T PL 10170694 T PL10170694 T PL 10170694T PL 2236151 T3 PL2236151 T3 PL 2236151T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor ligands
- melanocortin receptor
- melanocortin
- ligands
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69777905P | 2005-07-08 | 2005-07-08 | |
| US74885005P | 2005-12-09 | 2005-12-09 | |
| EP10170694A EP2236151B1 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
| EP06786665A EP1915167A4 (en) | 2005-07-08 | 2006-07-10 | MELANOCORTINREZEPTORLIGANDEN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2236151T3 true PL2236151T3 (pl) | 2012-10-31 |
Family
ID=37637790
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10182566T PL2286825T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
| PL17202836T PL3354273T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
| PL12188784T PL2548568T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
| PL10170694T PL2236151T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10182566T PL2286825T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
| PL17202836T PL3354273T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
| PL12188784T PL2548568T3 (pl) | 2005-07-08 | 2006-07-10 | Ligandy receptora melanokortyny |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US8039435B2 (pl) |
| EP (6) | EP3925614A3 (pl) |
| JP (4) | JP4734411B2 (pl) |
| KR (2) | KR100997177B1 (pl) |
| CN (5) | CN101676298A (pl) |
| AU (2) | AU2006269261B2 (pl) |
| BE (1) | BE2021C557I2 (pl) |
| CA (4) | CA3044795A1 (pl) |
| DK (4) | DK3354273T3 (pl) |
| ES (4) | ES2877349T3 (pl) |
| FR (1) | FR21C1060I2 (pl) |
| HU (4) | HUE055154T2 (pl) |
| IL (3) | IL188545A (pl) |
| NL (1) | NL301150I2 (pl) |
| NZ (2) | NZ580806A (pl) |
| PL (4) | PL2286825T3 (pl) |
| PT (4) | PT2286825T (pl) |
| RU (2) | RU2439079C2 (pl) |
| SG (1) | SG163585A1 (pl) |
| SI (1) | SI3354273T1 (pl) |
| WO (1) | WO2007008704A2 (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100997177B1 (ko) * | 2005-07-08 | 2010-11-29 | 입센 파마 에스.에이.에스 | 멜라노코르틴 수용체 리간드 |
| DE102007020152A1 (de) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Mittel zur antiinfektiven Behandlung eines Patienten |
| EP2148692B1 (en) | 2007-05-25 | 2017-01-25 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
| TR201815292T4 (tr) * | 2007-11-05 | 2018-11-21 | Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College | İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi. |
| KR101810110B1 (ko) | 2008-05-27 | 2017-12-18 | 젠자임 코포레이션 | 알파-멜라노사이트 자극 호르몬의 펩티드 유사체 |
| WO2009152079A1 (en) | 2008-06-09 | 2009-12-17 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| EA020959B1 (ru) | 2009-06-08 | 2015-03-31 | Палатин Текнолоджиз, Инк. | Пептиды, специфичные к меланокортиновым рецепторам |
| EP2440572B1 (en) | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| KR20120059520A (ko) * | 2009-08-05 | 2012-06-08 | 입센 파마 에스.에이.에스 | 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도 |
| ES2624451T3 (es) * | 2009-08-31 | 2017-07-14 | Tensive Controls, Inc. | Ligandos de melanocortina estabilizados |
| JP2013510881A (ja) * | 2009-11-16 | 2013-03-28 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法 |
| US9314509B2 (en) | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| EA021897B1 (ru) | 2009-11-23 | 2015-09-30 | Палатин Текнолоджиз, Инк. | Циклические пептиды, специфичные к рецептору меланокортина-1 |
| BR112012011780A2 (pt) | 2009-11-23 | 2019-09-24 | Palatin Technologies, Inc | peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| CA3301962A1 (en) | 2011-12-29 | 2026-03-02 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
| EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| WO2014060606A1 (en) | 2012-10-19 | 2014-04-24 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| EP2968475A2 (en) | 2013-03-14 | 2016-01-20 | Questcor Pharmaceuticals, Inc. | Acth for treatment of acute respiratory distress syndrome |
| US10196425B2 (en) * | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| PT2970389T (pt) * | 2013-03-15 | 2020-10-21 | Rhythm Pharmaceuticals Inc | Composições farmacêuticas |
| WO2015162485A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Peptide analogues with branched amino acid probe(s) |
| PT3356386T (pt) | 2015-09-30 | 2024-05-17 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados à via do receptor da melanocortina-4 |
| WO2017066754A1 (en) * | 2015-10-15 | 2017-04-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for the treatment of depression and anxiety |
| WO2018074999A1 (en) * | 2016-10-17 | 2018-04-26 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Novel modulators of melanocortin receptors for the treatment of depression and anxiety |
| US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
| JP2020514365A (ja) * | 2017-03-15 | 2020-05-21 | ノヴォ ノルディスク アー／エス | メラノコルチン４受容体に結合可能な二環式化合物 |
| AU2019249255A1 (en) | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
| WO2019219714A1 (en) * | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| WO2019222851A1 (en) * | 2018-05-23 | 2019-11-28 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
| US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
| EP4216979A4 (en) * | 2020-09-24 | 2024-11-06 | Rhythm Pharmaceuticals, Inc. | Methods of treating melanocortin-4 receptor pathway-associated disorders |
| MX2023011157A (es) * | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| US20240287154A1 (en) * | 2021-05-27 | 2024-08-29 | The Regents Of The University Of Michigan | Mc3r agonist peptides |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2025123051A1 (en) * | 2023-12-07 | 2025-06-12 | Endevica Bio, Inc. | Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain |
| WO2025245288A1 (en) * | 2024-05-22 | 2025-11-27 | Endevica Bio, Inc. | Non-naturally occurring melanocortin analogs and uses thereof |
| CN120699097A (zh) * | 2024-09-03 | 2025-09-26 | 万邦德制药集团有限公司 | 一种二硫环肽化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613874A (en) | 1898-11-08 | George e | ||
| US1613874A (en) | 1922-03-29 | 1927-01-11 | Miner Inc W H | Friction draft gear |
| US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| SE9700620D0 (sv) | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cykliska peptider med selektivitet för MSH-receptor subtyper |
| US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
| WO1999055679A1 (en) * | 1998-04-28 | 1999-11-04 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| CA2337495C (en) * | 1998-07-27 | 2008-03-18 | Iowa State University Research Foundation | Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals |
| WO2000010507A2 (en) | 1998-08-21 | 2000-03-02 | The Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
| US6716810B1 (en) | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| DK1165613T3 (da) | 1999-03-29 | 2008-08-25 | Procter & Gamble | Melanocortinreceptorligander |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| EP1241933B1 (en) | 1999-11-12 | 2008-10-01 | Merck & Co., Inc. | Melanocortin-3 receptor deficient cells, transgenic mice and methods of selecting compounds which regulate body weight |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| EA200201119A1 (ru) * | 2000-06-28 | 2003-06-26 | Пфайзер Продактс Инк. | Лиганды меланокортиновых рецепторов |
| US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| US6689938B2 (en) | 2000-09-13 | 2004-02-10 | Oklajoma Medical Research Foundation | Method for treatment of insulin resistance in obesity and diabetes |
| US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
| WO2002079146A2 (en) | 2001-03-02 | 2002-10-10 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| CA2453515A1 (en) * | 2001-07-11 | 2003-01-23 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
| US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| US20040128136A1 (en) * | 2002-09-20 | 2004-07-01 | Irani Pourang Polad | Internet voice browser |
| AU2004251616A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
| JP2006527772A (ja) | 2003-06-19 | 2006-12-07 | イーライ リリー アンド カンパニー | メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途 |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| CN100398536C (zh) * | 2003-08-20 | 2008-07-02 | 爱密斯菲尔科技公司 | 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂 |
| JP4767850B2 (ja) | 2003-08-20 | 2011-09-07 | エミスフィアー テクノロジーズ インコーポレイテッド | グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤 |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| EP1694348A4 (en) | 2003-12-10 | 2009-07-01 | Merck & Co Inc | INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS |
| JP2007530674A (ja) | 2004-03-29 | 2007-11-01 | イーライ リリー アンド カンパニー | 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用 |
| CN101076348A (zh) | 2004-10-08 | 2007-11-21 | 克里纽沃药物有限公司 | 用于在受试者中诱导黑素原生成的组合物和方法 |
| WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| WO2006073772A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| KR100997177B1 (ko) * | 2005-07-08 | 2010-11-29 | 입센 파마 에스.에이.에스 | 멜라노코르틴 수용체 리간드 |
| AU2005335905C1 (en) | 2005-08-26 | 2011-12-22 | Abbvie Inc. | Therapeutically active alpha-MSH analogues |
-
2006
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko active Active
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 CN CN201610168908.2A patent/CN105837661B/zh active Active
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko active Active
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es active Active
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja active Active
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es active Active
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es active Active
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 CN CN202411273113.9A patent/CN119119190A/zh active Pending
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh active Active
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh active Active
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es active Active
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en not_active Ceased
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
-
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
-
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja active Active
-
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
-
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
-
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja active Active
-
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
-
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-07 BE BE2021C557C patent/BE2021C557I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
-
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en not_active Abandoned
-
2025
- 2025-04-28 US US19/191,698 patent/US20260085092A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100054I1 (hu) | Melanokortin receptor ligandumok | |
| NL301034I2 (nl) | romosozumab | |
| NO2018008I1 (no) | Nivolumab | |
| DE602005006405D1 (de) | Maisabstreifer | |
| EP1850935A4 (en) | Amusement ride | |
| DE602006006870D1 (de) | Fexofenadinlösungsformulierung | |
| FI20055079A0 (fi) | Radiaalisiipipyörä | |
| DE112005003670A5 (de) | Eventanordnung | |
| FI20055078L (fi) | Yhteistoiminta | |
| DE602006021280D1 (de) | Effusionszellventil | |
| DE602006021721D1 (de) | Nadellager | |
| EP1877549A4 (en) | VACCINE AGAINST HIV | |
| ITRM20050271A1 (it) | Stuoia. | |
| DE102006033170A8 (de) | Einfassnähmaschine | |
| FI7102U1 (fi) | Istuin | |
| DE502006002564D1 (de) | Ndungen | |
| AT501968A3 (de) | Mitführhilfe | |
| EP1915490A4 (en) | DUCH TOUR ARRANGEMENT | |
| FR2887915B1 (fr) | Huisserie | |
| FIU20050156U0 (fi) | Runkopatjasänky | |
| FI20055601A7 (fi) | Kannatin | |
| UA11842S (uk) | Кронштейн | |
| SE0502247L (sv) | Referenslinje | |
| FI20040097A0 (fi) | Monikiinnitin | |
| DE502006007306D1 (de) | Halterungsanordnung |